Therapy Watch launches a new Migraine tracker
This multi country study will report on patients with Migraine prophylaxis. The new class of CGRP inhibitors (Aimovig, Ajovy, and Emgality) look set to shake up the migraine prophylaxis market, a market which has seen little innovation in the last decade and in which there still remains considerable unmet patient need.
Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).
Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter.
In addition from Q1 2019 Therapy Watch will now be tracking prescription topical treatments in both a secondary care and primary care setting providing broad visibility of the psoriasis market landscape.
Infographic: Psoriasis (PsO)
An overview of the PsO advanced therapy and systemic patient
Our PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot features profile data for patients treated with advanced therapy agents and systemic agents.
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient
Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data.